JG
INO icon

Jefferies Group’s Inovio Pharmaceuticals INO Stock Holding History

Jefferies Group’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-4,192
Closed -$467K – 1810
2021
Q1 		$467K Sell
4,192
-40,308
-91% -$5.3M ﹤0.01% 1143
2020
Q4 		$4.73M Buy
+44,500
New +$5.92M 0.04% 427

Other funds holding INO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jefferies Group's INO Position: Q4 2021 in Review

Jefferies Group sold out of Inovio Pharmaceuticals (INO) in Q4 2021, closing a stake of 313 shares — an estimated $26.9K sold.

Jefferies Group first reported a position in INO in Q2 2015 and held it in 5 quarters. The position peaked at $4.43M in Q4 2020. 208 funds tracked by Wall St. Rank hold INO as of Q4 2021.

  • Jefferies Group reported no remaining Inovio Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Jefferies Group sold 313 Inovio Pharmaceuticals shares in Q4 2021, an estimated $26.9K.
  • Jefferies Group first reported a position in Inovio Pharmaceuticals in Q2 2015 and held it in 5 quarters.
  • Jefferies Group's Inovio Pharmaceuticals position peaked at $4.43M in Q4 2020.
  • 208 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2021.

Based on Jefferies Group's 13F filing for Q4 2021, filed 14 Feb 2022.